Processing Magazine

FDA Approves New Version of Abbott Labs Cancer Drug

June 21, 2011

Abbott Laboratories said that the Food and Drug Administration has approved a formulation of its prostate cancer treatment Lupron Depot that allows patients to receive treatment every six months, reports the Associated Press. The company said the additional formulation gives it four, including ones that allow patients to receive treatment every month, three months or four months. Lupron is used as a palliative treatment for advanced prostate cancer. It suppresses the production of the hormone testosterone, which can help slow or stop the growth of hormone-dependent cancer cells and may relieve pain.